The Bcl-2-specific inhibitor venetoclax is highly cytotoxic for CLL cells and causes a rapid reduction in circulating CLL cells in the majority of patients, but LN responses are less complete [9]. The gene discussed is BCL2; the disease is B-cell chronic lymphocytic leukemia.